Trade

with

Infinity Pharmaceuticals Inc
(NASDAQ: INFI)
AdChoices
12.95
+0.17
+1.33%
After Hours :
12.95
0.00
0.00%

Open

12.53

Previous Close

12.78

Volume (Avg)

411.22k (982.67k)

Day's Range

12.47-13.19

52Wk Range

8.40-18.35

Market Cap.

629.19M

Dividend Rate ( Yield )

-

Beta

1.15

Shares Outstanding

48.59M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 0

    • Net Income

    • -126.78M

    • Market Cap.

    • 629.19M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.15

    • Forward P/E

    • -7.22

    • Price/Sales

    • -

    • Price/Book Value

    • 4.54

    • Price/Cash flow

    • -4.58

      • EBITDA

      • -124.96M

      • Return on Capital %

      • -64.92

      • Return on Equity %

      • -73.87

      • Return on Assets %

      • -64.92

      • Book Value/Share

      • 2.85

      • Shares Outstanding

      • 48.59M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Outperform
        • 1 Year Price Target

        • 15.00

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -1.77

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 6.04

              • 2.92

              • Quick Ratio

              • 5.33

              • 2.35

              • Interest Coverage

              • -35.09

              • 38.02

              • Leverage Ratio

              • 1.20

              • 2.21

              • Book Value/Share

              • 2.85

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -4.25

                • 238.10

                • P/E Ratio 5-Year High

                • -16.57

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.45

                • 124.82

                • Price/Sales Ratio

                • -

                • 8.94

                • Price/Book Value

                • 4.54

                • 8.12

                • Price/Cash Flow Ratio

                • -4.58

                • 47.85

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -73.87

                    (-59.50)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -64.92

                    (-31.10)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -71.83

                    (-46.70)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • -

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -127.68M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -4.58
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  66.02%

                  Mutual Fund Ownership

                  40.41%

                  Float

                  89.22%

                  5% / Insider Ownership

                  4.05%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Goldman Sachs Small Cap Value

                  •  

                    2,019,988

                  • -4.48

                  • 4.16

                  • Bb Biotech AG

                  •  

                    1,505,737

                  • 15.76

                  • 3.10

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    1,325,833

                  • 0.00

                  • 2.73

                  • SPDR® S&P Biotech ETF

                  •  

                    1,036,818

                  • 0.60

                  • 2.03

                  • Vanguard Small Cap Index

                  •  

                    802,918

                  • -0.09

                  • 1.65

                  • Vanguard Total Stock Mkt Idx

                  •  

                    770,519

                  • 0.09

                  • 1.59

                  • iShares Russell 2000 (AU)

                  •  

                    765,242

                  • -0.02

                  • 1.50

                  • Eaton Vance Worldwide Health Sciences Fu

                  •  

                    753,000

                  • 0.00

                  • 1.55

                  • Biotech Growth Trust Plc

                  •  

                    710,300

                  • 0.00

                  • 1.46

                  • iShares Nasdaq Biotechnology

                  •  

                    649,487

                  • 3.08

                  • 1.27

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    4,990,187

                  • +10.44%

                  • 10.27

                  • Orbimed Advisors, LLC

                  •  

                    4,736,900

                  • 0.00%

                  • 9.75

                  • Deerfield Management Co

                  •  

                    3,674,838

                  • -17.31%

                  • 7.56

                  • Goldman Sachs Asset Management, L.P.

                  •  

                    3,129,357

                  • +0.74%

                  • 6.44

                  • Vanguard Group, Inc.

                  •  

                    2,705,287

                  • +1.78%

                  • 5.57

                  • BlackRock Fund Advisors

                  •  

                    2,261,583

                  • +18.96%

                  • 4.65

                  • State Street Corp

                  •  

                    1,967,894

                  • -5.93%

                  • 4.05

                  • Wellington Management Company, LLP

                  •  

                    1,787,776

                  • +13.28%

                  • 3.68

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  Infinity Pharmaceuticals, Inc. was incorporated in California on March 22, 1995 under the name IRORI and, in 1998; the Company changed its name to Discovery Partners International, Inc. On September 12, 2006, Discovery Partners compl...moreeted a merger with Infinity Pharmaceuticals, Inc., to which a wholly-owned subsidiary of Discovery Partners merged with and into the Company. The Company is a biopharmaceutical company engaged in discovering, developing and delivering medicines to people with difficult-to-treat diseases. It combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. The IPI-145, its primary product candidate, is a potent, oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase, or PI3K. The P...moreI3K-delta and PI3K-gamma isoforms are preferentially expressed in white blood cells, where they have distinct and mostly non-overlapping roles in immune cell development and function. For Hematologic Malignancies, the Company has launched DUETTS, an investigation of IPI-145 in blood cancers. As part of the DUETTS program, it is conducting DYNAMO, a Phase 2, open-label, single arm study evaluating the safety and efficacy of IPI-145 dosed at 25mg BID in approximately 120 patients with indolent non-Hodgkin lymphoma, or iNHL, including follicular lymphoma, marginal zone lymphoma and small lymphocytic lymphoma, whose disease is refractory to radio immunotherapy or both rituximab and chemotherapy. The FDA has granted orphan drug designation to IPI-145 for the potential treatment of follicular lymphoma. It is conducting DUO, a randomized, monotherapy Phase 3 study of IPI-145 in approximately 300 patients with relapsed/refractory chronic lymphocytic leukemia. For Inflammation and Autoimmune Diseases, the Company has completed a Phase 1, randomized, double-blind, placebo-controlled trial of IPI-145 in healthy adult subjects designed to support the development of IPI-145 in inflammatory and autoimmune diseases. The Company is also developing its second PI3K product candidate, a potent, oral inhibitor of PI3K-delta and gamma referred to as IPI-443. The nonclinical studies of IPI-443 required for Phase 1 development have been completed, and the data from the two Phase 2 studies of IPI-145 in inflammatory and autoimmune diseases will guide the next steps for the development of IPI-443. The Company has discovered IPI-940, a novel, orally available inhibitor of fatty acid amide hydrolase. It is believed that inhibition of FAAH may enable the body to bolster its own analgesic and anti-inflammatory response and may have applicability in a broad range of painful or inflammatory conditions. The Company has five issued or allowed U.S. patents covering IPI-145 and/or other molecules related to PI3K program, which expires on various dates between 2029 and 2031. In addition, it has approximately 170 patents and patent applications pending related to PI3K program.lessless

                  Key People

                  Ms. Adelene Q. Perkins

                  CEO/Chairman of the Board/Director/President

                  Lawrence E. Bloch,M.D.,J.D.

                  Secretary/Treasurer/CFO/Chief Accounting Officer/Executive VP/Other Executive Officer

                  Joshua Hamermesh

                  Vice President, Divisional

                  Dr. Anthony B. Evnin,PhD

                  Director

                  Dr. Michael C. Venuti,PhD

                  Director

                  • Infinity Pharmaceuticals Inc

                  • 780 Memorial Drive

                  • Cambridge, MA 02139

                  • USA.Map

                  • Phone: +1 617 453-1000

                  • Fax: +1 617 453-1001

                  • infi.com

                  Incorporated

                  1995

                  Employees

                  180

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: